News
Tecentriq may be used with the medicines cobimetinib and vemurafenib in patients with melanoma when their skin cancer: has spread to other parts of the body or cannot be removed by surgery, and; ...
Roche’s Tecentriq With Lurbinectedin Increases Survival From Small-Cell Lung Cancer, Study Says Late-stage trials showed the combination led to a 27% reduction in the risk of death, the company said ...
Tecentriq can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life ...
Tecentriq can cause serious side effects, including: Lung problems (pneumonitis)–signs and symptoms of pneumonitis may include new or worsening cough, shortness of breath, and chest pain ...
The Tecentriq combination showed a statistically significant improvement in RFS in t. Genentech, a unit of Roche Holdings AG (OTC: RHHBY), ...
Tecentriq is available as a liquid solution that’s given as an IV infusion (an injection into your vein over a period of time). You’ll receive infusions at your doctor’s office or a clinic.
Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III studyTecentriq approval offers an alternative to chemotherapy for ...
Genentech, a member of the Roche Group, today announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq ® met its co-primary endpoints. "By reducing the ...
Tecentriq with chemotherapy did not significantly improve EFS in TNBC patients, with a four-year EFS rate of 85.2% versus 81.9% for placebo. No overall survival benefit was observed with Tecentriq, ...
Patients assigned Tecentriq had a median overall survival of 10.3 months compared with 9.2 months in those assigned chemotherapy. The two-year survival rate for the Tecentriq group was 24% versus 12% ...
Roche said Tecentriq combined with lurbinectedin shows significant survival benefits for patients with extensive-stage small cell lung cancer. The Swiss pharmaceutical company said Tuesday that ...
Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer – 46% reduction in the risk of disease progression or death, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results